SPONSOR
L & L Bio Co., Ltd., Ningbo, China
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 1, Phase 2
L & L Bio Co., Ltd., Ningbo, China is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Solid Tumor, Lymphoma.
The trial portfolio spans Phase 1, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — L & L Bio Co., Ltd., Ningbo, China
How many clinical trials has L & L Bio Co., Ltd., Ningbo, China sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by L & L Bio Co., Ltd., Ningbo, China, of which 2 are actively recruiting participants. These trials cover conditions including Solid Tumor, Lymphoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does L & L Bio Co., Ltd., Ningbo, China research focus on?
L & L Bio Co., Ltd., Ningbo, China clinical trials span Solid Tumor, Lymphoma. The research pipeline includes Phase 1, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a L & L Bio Co., Ltd., Ningbo, China clinical trial?
To participate in a L & L Bio Co., Ltd., Ningbo, China trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all L & L Bio Co., Ltd., Ningbo, China trials with current recruitment status updated daily.
Clinical Trials by L & L Bio Co., Ltd., Ningbo, China
NCT05357651 Phase 1
Recruiting
A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001）
Solid Tumor
NCT06468358 Phase 1, Phase 2
Recruiting
A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors
Solid Tumor
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology